Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian R Watson

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
British Journal of Cancer|June 24, 2016
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapiesShivshankari Rajkumar, Ian R Watson
Neoplasia (New York, N.Y.)|August 24, 2006
Ubiquitin and ubiquitin-like modifications of the p53 familyIan R Watson, Meredith S Irwin
Cancer Cell|February 15, 2011
NEDD8 pathways in cancer, Sine Quibus NonIan R Watson, Meredith S Irwin, Michael Ohh
Nature Reviews. Genetics|September 12, 2013
Emerging patterns of somatic mutations in cancerIan R Watson, Koichi Takahashi, P Andrew Futreal, et al.
Clinical & Experimental Metastasis|January 13, 2024
Mapping the single cell spatial immune landscapes of the melanoma microenvironmentJamie Magrill, Dan Moldoveanu, Jiayao Gu, et al.
Journal of Virology|August 25, 2006
Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral responseIrene I L Hwang, Ian R Watson, Sandy D Der, et al.
Plos One|June 27, 2013
Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivityAlvaro Blanch, Fiona Robinson, Ian R Watson, et al.
The Journal of Biological Chemistry|September 19, 2006
Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation functionIan R Watson, Alvaro Blanch, Dan C C Lin, et al.
Oncogene|March 16, 2018
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutationsMatthew Dankner, April A N Rose, Shivshankari Rajkumar, et al.
Cancer Research|November 19, 2009
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cellsAndrew M Roberts, Ian R Watson, Andrew J Evans, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|June 24, 2016
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapiesShivshankari Rajkumar, Ian R Watson
Neoplasia (New York, N.Y.)|August 24, 2006
Ubiquitin and ubiquitin-like modifications of the p53 familyIan R Watson, Meredith S Irwin
Cancer Cell|February 15, 2011
NEDD8 pathways in cancer, Sine Quibus NonIan R Watson, Meredith S Irwin, Michael Ohh
Nature Reviews. Genetics|September 12, 2013
Emerging patterns of somatic mutations in cancerIan R Watson, Koichi Takahashi, P Andrew Futreal, et al.
Clinical & Experimental Metastasis|January 13, 2024
Mapping the single cell spatial immune landscapes of the melanoma microenvironmentJamie Magrill, Dan Moldoveanu, Jiayao Gu, et al.
Journal of Virology|August 25, 2006
Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral responseIrene I L Hwang, Ian R Watson, Sandy D Der, et al.
Plos One|June 27, 2013
Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivityAlvaro Blanch, Fiona Robinson, Ian R Watson, et al.
The Journal of Biological Chemistry|September 19, 2006
Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation functionIan R Watson, Alvaro Blanch, Dan C C Lin, et al.
Oncogene|March 16, 2018
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutationsMatthew Dankner, April A N Rose, Shivshankari Rajkumar, et al.
Cancer Research|November 19, 2009
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cellsAndrew M Roberts, Ian R Watson, Andrew J Evans, et al.
Pageof 4